Parkinson's dementia

Bio & Pharma NKMax to perform first tests on dementia cell therapy in US

NKMax Co., South Korea's largest developer of natural killer (NK) cell therapies, will conduct its first clinical trials in the US for its candidate...

Bio & Pharma Humedix gets gov't OK for trials of dementia candidate drug

South Korea’s Humedix Co., a developer of biological and pharmaceutical products, on Tuesday said it received approval from the Ministry of Fo...

Artificial intelligence Vuno's brain imaging AI medical device secures FDA certification

South Korea's medical device startup Vuno announced on Tuesday that its AI-powered brain quantification device Vuno Med-DeepBrain has received the 5...

Bio & Pharma NGeneBio applies for US patent of early diagnosis tech of dementia

South Korean medical diagnostic company NGeneBio Co. announced on Thursday that it has completed the US patent application for its technology relate...

Bio & Pharma AriBio to sell dementia drug AR1001 in China with partner

South Korea's clinical-stage biotech company AriBio Co. on Wednesday said it signed a memorandum of understanding on strategic cooperation with Chin...

Bio & Pharma AriBio applies for Phase 3 clinical trials in China for oral dementia drug

South Korean clinical-stage biotech company AriBio Co. on Thursday said it applied for Phase 3 clinical trials on the anti-Alzheimer's candidate t...

Bio & Pharma Daehwa Pharm applies for approval of anti-dementia patch in China

South Korea's Daehwa Pharm Co. is speeding up its advance into the Chinese market for anti-dementia medicine, applying for sales approval of its pat...

Bio & Pharma HanAll, Daewoong to develop Parkinson's treatment with US partner

South Korea's HanAll Biopharma Co. and Daewoong Pharmaceutical on Thursday said they concluded a contract with NurrOn Pharmaceuticals of the US on...

Bio & Pharma S.Biomedics gets approval for Parkinson's disease clinical trials

South Korea's biomedicine firm S.Biomedics said on Friday that it has won approval from the Ministry of Food and Drug Safety for phase 1 and 2a clin...

Pharmaceuticals ABL Bio in $1.06 bn deal with Sanofi for Parkinson's disease treatment

South Korea’s ABL Bio Inc. has signed a $1.06 billion contract to license out its technology for a Parkinson's disease treatment candidate t...